124 related articles for article (PubMed ID: 9713510)
21. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.
Ng IO; Liu CL; Fan ST; Ng M
Am J Clin Pathol; 2000 Mar; 113(3):355-63. PubMed ID: 10705815
[TBL] [Abstract][Full Text] [Related]
22. The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis.
Ulbright TM; Orazi A; de Riese W; de Riese C; Messemer JE; Foster RS; Donohue JP; Eble JN
Mod Pathol; 1994 Jan; 7(1):64-8. PubMed ID: 7909155
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
24. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
25. [Lung resistance protein analysis in testicular cancer].
Mándoky L; Géczi L; Doleschall Z; Csuka O; Bodrogi I; Bak M
Magy Onkol; 2002; 46(4):339-45. PubMed ID: 12563357
[TBL] [Abstract][Full Text] [Related]
26. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression.
Hsia TC; Lin CC; Wang JJ; Ho ST; Kao A
Lung; 2002; 180(3):173-9. PubMed ID: 12177731
[TBL] [Abstract][Full Text] [Related]
27. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
28. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
29. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
30. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior.
Staibano S; Franco R; Tranfa F; Mezza E; Lo Muzio L; Strianese D; Errico ME; Bufo P; Ferrara G; Somma P; Mansueto G; Greco I; Fiorillo A; Bonavolontà G; De Rosa G
Anticancer Res; 2004; 24(1):249-57. PubMed ID: 15015604
[TBL] [Abstract][Full Text] [Related]
31. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices.
Ioachim EE; Charchanti AV; Stavropoulos NE; Athanassiou ED; Michael MC; Agnantis NJ
Anticancer Res; 2001; 21(3B):1757-61. PubMed ID: 11497256
[TBL] [Abstract][Full Text] [Related]
32. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
Chevillard S; Lebeau J; Pouillart P; de Toma C; Beldjord C; Asselain B; Klijanienko J; Fourquet A; Magdelénat H; Vielh P
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2471-8. PubMed ID: 9815649
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of cyclin expression in testicular germ cell tumors: cyclin E correlates with tumor type, advanced clinical stage, and pulmonary metastasis.
Datta MW; Renshaw AA; Dutta A; Hoffman MA; Loughlin KR
Mod Pathol; 2000 Jun; 13(6):667-72. PubMed ID: 10874672
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of metallothionein and p53 expression as potential prognostic markers for laryngeal squamous cell carcinoma.
Brown JJ; Xu H; William-Smith L; Mohamed H; Teklehaimanot S; Zhuo J; Osborne R; Liu F; Gowans RE; Nishitani J; Liu X
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL473-9. PubMed ID: 14995078
[TBL] [Abstract][Full Text] [Related]
35. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer.
Bani-Hani KE; Almasri NM; Khader YS; Sheyab FM; Karam HN
Clin Cancer Res; 2005 Feb; 11(4):1447-53. PubMed ID: 15746045
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract][Full Text] [Related]
37. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor-beta expression in human testicular germ cell tumors.
Pais V; Leav I; Lau KM; Jiang Z; Ho SM
Clin Cancer Res; 2003 Oct; 9(12):4475-82. PubMed ID: 14555521
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of doxorubicin in human bladder tumors.
Gan Y; Wientjes MG; Badalament RA; Au JL
Clin Cancer Res; 1996 Aug; 2(8):1275-83. PubMed ID: 9816297
[TBL] [Abstract][Full Text] [Related]
40. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
